Rebound, the results of the joint creation test of E7386 and lenvatinib mesylate co-developed by the company and Eisai will be announced by Eisai at the European Clinical Oncology Society Annual Meeting (ESMO Congress 2024), and it is considered as good news. The manageable safety of E7386 and lenvatinib combination therapy has been demonstrated, and preliminary anti-tumor effects have also been confirmed. The administration to the remaining patients is continuing.
ＰＲＩＳＭＢｉｏ---反発、E7386とレンバチニブメシル酸塩との併用試験の結果が「欧州臨床腫瘍学会年次総会」で発表へ
PRISM Bio - The results of the combination trial with E7386 and lenvatinib mesylate will be presented at the European Clinical Oncology Congress.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated